The Oncology Institute, Inc.
TOI
$2.71
$0.3213.39%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 21.33% | 22.29% | 23.31% | 25.30% | 28.42% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 21.33% | 22.29% | 23.31% | 25.30% | 28.42% |
| Cost of Revenue | 28.24% | 30.57% | 30.11% | 29.88% | 32.08% |
| Gross Profit | -9.36% | -11.65% | -4.31% | 6.63% | 14.36% |
| SG&A Expenses | -5.30% | -4.11% | -5.75% | -4.74% | -3.98% |
| Depreciation & Amortization | 7.05% | 12.19% | 27.58% | 29.83% | 33.14% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.98% | 19.45% | 18.14% | 17.87% | 18.87% |
| Operating Income | 0.08% | -4.93% | 4.54% | 11.18% | 15.15% |
| Income Before Tax | 22.19% | 6.45% | -17.91% | -47.52% | -91,223.08% |
| Income Tax Expenses | -- | -252.81% | 27.82% | 78.89% | 85.19% |
| Earnings from Continuing Operations | 22.16% | 6.75% | -18.10% | -48.50% | -54,750.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 22.16% | 6.75% | -18.10% | -48.50% | -54,750.00% |
| EBIT | 0.08% | -4.93% | 4.54% | 11.18% | 15.15% |
| EBITDA | 0.85% | -4.21% | 7.11% | 14.13% | 18.35% |
| EPS Basic | 23.34% | 7.47% | -18.04% | -48.15% | -28,048.48% |
| Normalized Basic EPS | 5.36% | -27.87% | -60.15% | -63.02% | -35.89% |
| EPS Diluted | 22.90% | 14.89% | 11.31% | -6.08% | -308.62% |
| Normalized Diluted EPS | 5.36% | -27.87% | -62.19% | -65.10% | -39.53% |
| Average Basic Shares Outstanding | 1.92% | 1.43% | 1.17% | 1.34% | 1.14% |
| Average Diluted Shares Outstanding | 1.92% | 1.43% | -1.33% | -1.17% | -2.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |